Individual investors eyeing opportunities in the biopharmaceutical sector may find Alkermes plc (NASDAQ: ALKS) a compelling consideration. As a leading player in the healthcare industry, Alkermes focuses on developing innovative treatments for neurological and psychiatric conditions, addressing significant unmet medical needs. Headquartered in Dublin, Ireland, the company boasts a market capitalization of $5.27 billion, marking it as a substantial entity in the drug manufacturing landscape.

Currently trading at $31.91, Alkermes shares are near the midpoint of their 52-week range of $26.13 to $35.52. The stock has shown resilience despite the recent price change reflecting a neutral day of trading. The company’s performance…